angina
Conditions
Interventions
Sponsors
Run Run Shaw Hospital, Zhejiang University School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Angina pectoris still occurred within 3 to 18 months after PCI treatment, which was treated and managed according to the Guidelines for Percutaneous Coronary Intervention in China (2016); 2. Patients with stable exertive angina who had >= 2 angina attacks per week in the previous month and whose severity was classified as Canadian Angina severity Scale (CCS) I - III; 3. Patients with ST segment depression or T wave inversion on electrocardiogram, positive motion plate or ischemic changes assessed by SPECT, PET, MRI, CT and other imaging.; 4. Patients who stopped using drugs for activating blood circulation and removing blood stasis for more than 2 weeks. 5. Aged 18 to 80 years, male or female; 6. Voluntarily participate in the study and sign the informed consent.
Exclusion criteria
Exclusion criteria: 1. Those eligible for revascularization; 2. Patients with cardiac function grade IV (NYHA scale, see Appendix 2) or CCS GradeIV (Canadian Angina severity Scale); 3. Patients with uncontrolled grade 3 hypertension (systolic blood pressure >= 180mmHg and/or diastolic blood pressure >= 110mmHg), severe cardiopulmonary insufficiency, severe arrhythmia, serious primary diseases of liver, kidney and hematopoietic system, or serious diseases affecting their survival (such as tumor) and mental illness; 4. Combined with other clinical conditions that may increase the risk of bleeding, such as a history of major organ bleeding in the last six months (such as cerebral hemorrhage, upper gastrointestinal bleeding, etc.), platelet count less than 50 × 10^9/L, abnormal coagulation function, and oral warfarin anticoagulation treatment, etc.; 5. Abnormal indexes of liver and kidney function (ALT, AST, Scr, BUN 3 times higher than the upper limit of normal reference range); 6. Patients with allergic constitution, or food allergy to multiple drugs, or patients known to be allergic to the study drug (including its ingredients); 7. Those who have a pregnancy plan; 8. Breast-feeding women; 9. Vulnerable groups: including neurological diseases, cognitive impairment, critically ill patients, minors, pregnant women, etc.; 10.Patients who participated in other clinical trials within the last 1 month; 11.Other reasons concluded by the investigator suggested that the patients were not eligible for inclusion.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Peak VO2; | — |
Secondary
| Measure | Time frame |
|---|---|
| Maximum exercise load;Start time of ST segment depression or elevation by 1mm;Maximal oxygen uptake without oxygen threshold;Maximal oxygen uptake without oxygen threshold/heart rate, VO2/HR;METs(Metabolic Equivalents);Generalized Anxiety Disorder 7-item, GAD-7;Patient Health Questionnaire-9, PHQ-9;Angina symptom score;Canadian classification of angina severity;Weber classification of cardiac function;Major Adverse Cardiac Event, MACE; | — |
Countries
China
Contacts
Public ContactFu Guosheng
Run Run Shaw Hospital, Zhejiang University School of Medicine
Outcome results
None listed